1-4 of 4
Ben Markman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1017–1030.
https://doi.org/10.1158/1078-0432.CCR-22-3094
Published: 14 March 2023
View article titled, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Open the PDF for A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study in another window
Includes: Supplementary data
Journal Articles

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, Matteo Duca, Giuseppe Curigliano, Armando Santoro, Takafumi Koyama, Michelle Brown, Heather Vezina, Chunsheng He, Quincy Siu-Chung Chu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 95–105.
https://doi.org/10.1158/1078-0432.CCR-21-1181
Published: 01 January 2022
View article titled, Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Open the PDF for Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4454–4459.
https://doi.org/10.1158/1078-0432.CCR-20-0621
Published: 01 September 2020
View article titled, Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Open the PDF for Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (9): 2445–2456.
https://doi.org/10.1158/1078-0432.CCR-13-2403
Published: 30 April 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data